109 related articles for article (PubMed ID: 31058551)
1. Impact of Weight Loss During Chemotherapy in Chinese Patients with Unresectable Pancreatic Cancer.
Wong HCY; Lam KY; Chong CCN; Chan AWH; Chan SL
Nutr Cancer; 2019; 71(6):954-970. PubMed ID: 31058551
[No Abstract] [Full Text] [Related]
2. Critical weight loss predicts poor prognosis in nasopharyngeal carcinoma.
Zeng Q; Shen LJ; Guo X; Guo XM; Qian CN; Wu PH
BMC Cancer; 2016 Feb; 16():169. PubMed ID: 26926144
[TBL] [Abstract][Full Text] [Related]
3. Effect of clinical status on survival in patients with borderline or locally advanced pancreatic adenocarcinoma.
Duconseil P; Garnier J; Weets V; Ewald J; Marchese U; Gilabert M; Moureau-Zabotto L; Poizat F; Giovannini M; Delpero JR; Turrini O
World J Surg Oncol; 2019 Jun; 17(1):95. PubMed ID: 31164144
[TBL] [Abstract][Full Text] [Related]
4. Protein intake after the initiation of chemotherapy is an independent prognostic factor for overall survival in patients with unresectable pancreatic cancer: A prospective cohort study.
Hasegawa Y; Ijichi H; Saito K; Ishigaki K; Takami M; Sekine R; Usami S; Nakai Y; Koike K; Kubota N
Clin Nutr; 2021 Jul; 40(7):4792-4798. PubMed ID: 34265503
[TBL] [Abstract][Full Text] [Related]
5. Impact of the treatment of pancreatic exocrine insufficiency on survival of patients with unresectable pancreatic cancer: a retrospective analysis.
Domínguez-Muñoz JE; Nieto-Garcia L; López-Díaz J; Lariño-Noia J; Abdulkader I; Iglesias-Garcia J
BMC Cancer; 2018 May; 18(1):534. PubMed ID: 29728096
[TBL] [Abstract][Full Text] [Related]
6. Unresectable pancreatic ductal adenocarcinoma: Role of CT quantitative imaging biomarkers for predicting outcomes of patients treated with chemotherapy.
Cheng SH; Cheng YJ; Jin ZY; Xue HD
Eur J Radiol; 2019 Apr; 113():188-197. PubMed ID: 30927946
[TBL] [Abstract][Full Text] [Related]
7. Prognostic factors in patients with advanced pancreatic cancer treated with gemcitabine alone or gemcitabine plus cisplatin: retrospective analysis of a multicenter study.
Inal A; Kos FT; Algin E; Yildiz R; Berk V; Tugba Unek I; Colak D; Colak D; Kucukoner M; Tamer Elkiran E; Helvaci K; Geredeli C; Dane F; Balakan O; Ali Kaplan M; Gok Durnali A; Harputoglu H; Goksel G; Ozdemir N; Buyukberber S; Gumus M; Ozkan M; Benekli M; Isikdogan A;
J BUON; 2012; 17(1):102-5. PubMed ID: 22517701
[TBL] [Abstract][Full Text] [Related]
8. Chemotherapy-induced neutropenia as a prognostic factor in patients with pancreatic cancer treated with gemcitabine plus nab-paclitaxel: a retrospective cohort study.
Kan M; Imaoka H; Watanabe K; Sasaki M; Takahashi H; Hashimoto Y; Ohno I; Mitsunaga S; Umemoto K; Kimura G; Suzuki Y; Eguchi H; Otsuru T; Goda K; Ikeda M
Cancer Chemother Pharmacol; 2020 Aug; 86(2):203-210. PubMed ID: 32632515
[TBL] [Abstract][Full Text] [Related]
9. Neutrophil-to-lymphocyte ratio for predicting palliative chemotherapy outcomes in advanced pancreatic cancer patients.
Xue P; Kanai M; Mori Y; Nishimura T; Uza N; Kodama Y; Kawaguchi Y; Takaori K; Matsumoto S; Uemoto S; Chiba T
Cancer Med; 2014 Apr; 3(2):406-15. PubMed ID: 24519894
[TBL] [Abstract][Full Text] [Related]
10. Clinical significance of skeletal muscle density and sarcopenia in patients with pancreatic cancer undergoing first-line chemotherapy: a retrospective observational study.
Kim IH; Choi MH; Lee IS; Hong TH; Lee MA
BMC Cancer; 2021 Jan; 21(1):77. PubMed ID: 33461517
[TBL] [Abstract][Full Text] [Related]
11. Prognostic factors of unresectable pancreatic cancer treated with nafamostat mesilate combined with gemcitabine chemotherapy.
Furukawa K; Uwagawa T; Iwase R; Haruki K; Fujiwara Y; Gocho T; Shiba H; Misawa T; Yanaga K
Anticancer Res; 2012 Nov; 32(11):5121-6. PubMed ID: 23155291
[TBL] [Abstract][Full Text] [Related]
12. Randomized Phase II Study of Consecutive-Day versus Alternate-Day Treatment with S-1 as Second-Line Chemotherapy in Advanced Pancreatic Cancer.
Ishikawa T; Kawashima H; Ohno E; Matsubara H; Sasaki Y; Achiwa K; Kanamori A; Sumi H; Hirai T; Nonogaki K; Tsuzuki T; Kuroiwa M; Hattori M; Maruta S; Hiramatsu T; Ando M; Hashimoto S; Hirooka Y
Oncology; 2019; 96(1):1-7. PubMed ID: 30368509
[TBL] [Abstract][Full Text] [Related]
13. nab-Paclitaxel plus gemcitabine for metastatic pancreatic cancer: long-term survival from a phase III trial.
Goldstein D; El-Maraghi RH; Hammel P; Heinemann V; Kunzmann V; Sastre J; Scheithauer W; Siena S; Tabernero J; Teixeira L; Tortora G; Van Laethem JL; Young R; Penenberg DN; Lu B; Romano A; Von Hoff DD
J Natl Cancer Inst; 2015 Feb; 107(2):. PubMed ID: 25638248
[TBL] [Abstract][Full Text] [Related]
14. The association of weight loss with one-year mortality in hospital patients, stratified by BMI and FFMI subgroups.
de van der Schueren MAE; de Smoker M; Leistra E; Kruizenga HM
Clin Nutr; 2018 Oct; 37(5):1518-1525. PubMed ID: 28890273
[TBL] [Abstract][Full Text] [Related]
15. The prognostic role of soluble TGF-beta and its dynamics in unresectable pancreatic cancer treated with chemotherapy.
Park H; Bang JH; Nam AR; Park JE; Jin MH; Bang YJ; Oh DY
Cancer Med; 2020 Jan; 9(1):43-51. PubMed ID: 31701645
[TBL] [Abstract][Full Text] [Related]
16. Impact on prognosis of early weight loss during palliative chemotherapy in patients diagnosed with advanced pancreatic cancer.
Carnie L; Abraham M; McNamara MG; Hubner RA; Valle JW; Lamarca A
Pancreatology; 2020 Dec; 20(8):1682-1688. PubMed ID: 33046391
[TBL] [Abstract][Full Text] [Related]
17. The relation between inflammation-based parameters and survival in metastatic pancreatic cancer.
Turker S; Cilbir E; Guven DC; Karacin C; Yalcin S
J Cancer Res Ther; 2021; 17(2):510-515. PubMed ID: 34121700
[TBL] [Abstract][Full Text] [Related]
18. Prognostic value of early changes in CT-measured body composition in patients receiving chemotherapy for unresectable pancreatic cancer.
Salinas-Miranda E; Deniffel D; Dong X; Healy GM; Khalvati F; O'Kane GM; Knox J; Bathe OF; Baracos VE; Gallinger S; Haider MA
Eur Radiol; 2021 Nov; 31(11):8662-8670. PubMed ID: 33934171
[TBL] [Abstract][Full Text] [Related]
19. Prognostic factors in patients with metastatic or recurrent pancreatic cancer treated with first-line nab-paclitaxel plus gemcitabine: implication of inflammation-based scores.
Hwang I; Kang J; Ip HNN; Jeong JH; Kim KP; Chang HM; Yoo C; Ryoo BY
Invest New Drugs; 2019 Jun; 37(3):584-590. PubMed ID: 30324344
[TBL] [Abstract][Full Text] [Related]
20. The Impact of Critical Weight Loss and Reactive Feeding Tubes on Cancer-Specific Survival in Head and Neck Cancer.
Vangelov B; Kotevski DP; Smee RI
Nutr Cancer; 2021; 73(2):262-272. PubMed ID: 32281392
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
